Whitehawk Therapeutics, Inc. Segments Disclosure
15. Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has identified its as the chief operating decision maker and the Company views its operations and manages its business in one operating segment, applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. The CODM assesses performance for the Company's single operating segment and decides how to allocate resources based on research and development expenses incurred and on net (loss) income as reported on the statement of operations and comprehensive (loss) income. The measure of segment assets is reported on the balance sheet as total assets. Further, segment depreciation expense
and segment asset additions are consistent with amounts reported within the statement of cash flows given the Company's operations are aggregated within a single reportable segment. The Company's revenues relate to sales of FYARRO, which was divested as of March 25, 2025. Refer to Note 2 for further information. All the assets and operations of the Company’s sole operating and reportable segment are located in the United States.
Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to net loss (in thousands):
|
|
Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Total Revenue |
|
$ |
7,145 |
|
|
$ |
25,983 |
|
Less: |
|
|
|
|
|
|
||
ADC assets - research and development expenses |
|
|
59,092 |
|
|
|
6,000 |
|
ADC assets - contract manufacturing expenses |
|
|
26,703 |
|
|
|
— |
|
FYARRO - research and development expenses |
|
|
5,168 |
|
|
|
34,338 |
|
FYARRO - contract manufacturing expenses |
|
|
— |
|
|
|
10,692 |
|
FYARRO - commercial and marketing expenses |
|
|
294 |
|
|
|
2,130 |
|
Finance and accounting expenses (1) |
|
|
9,349 |
|
|
|
11,758 |
|
Legal expenses |
|
|
5,815 |
|
|
|
7,437 |
|
Other segment items (2) |
|
|
(78,680 |
) |
|
|
17,319 |
|
Net loss |
|
$ |
(20,596 |
) |
|
$ |
(63,691 |
) |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 12, 2026 | Showing above |
| 2024 | Mar 28, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.